47 results about "Stent thrombosis" patented technology

The invention provides methods and compositions for determining whether a subject containing a stent immobilized in a blood vessel has asymptomatic stent thrombosis or is at risk of developing clinically symptomatic stent thrombosis. In one approach, the method involves imaging a region of the blood vessel that contains the stent using a probe that contains a fluorochrome, for example, a near-infrared fluorochrome, and a targeting moiety that binds a molecular marker indicative of the presence of asymptomatic stent thrombosis or the development of symptomatic stent thrombosis. To the extent that the subject displays one or more such markers, the probe binds to the markers and increases the local concentration of the probe in the vicinity of the stent. The imaging method identifies those patients that display a higher density of such markers in the vicinity of the stent. As a result, those patients can be monitored for, and / or treated to prevent, symptomatic stent thrombosis.

The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.

Methods of treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.

The invention relates to a degradable zinc-based alloy bracket and a preparation method thereof. The bracket includes a degradable zinc-based material bracket substrate; the surface of the bracket substrate is provided with a degradable polymer eluting coating containing treatment drug; the bracket substrate is a cylindrical mesh structure. The preparation method includes: 1) processing the degradable zinc-based material to be a bracket substrate; 2) performing the surface pretreatment on the bracket substrate; 3) performing electrochemical polishing treatment on the bracket substrate; 4) after the treatment, coating a degradable high polymer material carrying with treatment drug on the surface of the bracket. For the substrate material zinc alloy has excellent corrosive resistance, the bracket provided by the invention keeps good supporting property after implanting for 4 months above; the substrate surface is coated with the polymer coating with good biocompatibility, thus the improved compatibility of the zinc-based alloy is good for the coverage of endothelial cells at the surface of the bracket; the drug release can be controlled, and drug burst release is reduced, so that the drug can be released slowly and sustainably with a certain concentration, so as to reduce the local inflammation, restenosis and stent thrombosis risk after implanting the bracket.

Methods of treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.

A method of treating or preventing a disease or condition in a subject that was previously treated with at least one thienopyridine is described. The method includes administering to the subject an effective amount of at least one reversible, short-acting P2Yi2 inhibitor. The described method can be used for subjects diagnosed with symptoms such as stable or unstable angina, vascular ischemic events, atherosclerosis, acute coronary syndrome, as well as STEMi or N-STEMI. The described method can also be used for patients having previously received a stent, such as a bare metal stent or a drug-eluting stent, and the treatment or prevention of stent thrombosis. The method can be used prior to, during, or after an invasive procedure such as coronary artery bypass grafting, percutaneous coronary intervention, or other general surgical procedure.

Methods of treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor, and optionally bivalirudin. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.

A method of treating or preventing a disease or condition in a subject that was previously treated with at least one thienopyhdine is described. The method includes administering to the subject an effective amount of at least one reversible, short-acting P2Yi2 inhibitor. The described method can be used for subjects diagnosed with symptoms such as stable or unstable angina, vascular ischemic events, atherosclerosis, acute coronary syndrome, as well as STEMi or N-STEMI. The described method can also be used for patients having previously received a stent, such as a bare metal stent or a drug-eluting stent, and the treatment or prevention of stent thrombosis. The method can be used prior to, during, or after an invasive procedure such as coronary artery bypass grafting, percutaneous coronary intervention, or other genera! surgical procedure.

Methods of treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.

The invention discloses use of a novel bioresorbable slide fastener scaffold as a cardiovascular system scaffold or endoluminal stent for cardiovascular disease or luminal stenosis disease. The invention has the advantages that: the novel bioresorbable slide fastener scaffold has good degradability and biocompatibility, is more suitable for a blood vessel scaffold in paediatrics, and cannot causelate stent thrombosis after being implanted so as to ensure that the patient does not need taking an anti-platelet agent for a long time and the subsequently possible surgical operation cannot be influenced; the novel bioresorbable slide fastener scaffold has strong support force, and can serve as the cardiovascular system scaffold or endoluminal stent to be widely applied to the cardiovascular disease or luminal stenosis disease; the novel bioresorbable slide fastener scaffold is easy and convenient to manufacture, is convenient to load medicines and can be used as a carrier of medicines or a vector for gene therapy; the scaffold is equipped with a deliver system to reduce the surgical operating difficulty; and a large number of animal experiments prove that the novel bioresorbable slidefastener scaffold has higher success rate during use, obvious treatment effect and better clinical application prospect.

The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.

The invention relates to a tranilast medicine coat controlled release eluting bracket, pertaining to the field of medicine and medical appliance. The invention takes tranilast as the active component;three layers of a medicine loading layer, a controlled release layer and a protecting film layer are at the surface of the bracket. The bracket coat is evenly distributed on the surface of the bracket without crack and exfoliating phenomena; the original morphological structure can be kept after expanding. Proved by animal experiment result, the invention can effectively restrain the coronary hyperplasia and restenosis and markedly reduce the function of restraining the blood vessel endothelial cell at the same time; compared with the single coat or double coat structure of the existing drug-eluting bracket, the bracket of the invention can prevent the restenosis of the bracket, and has the functions of prventing bracket thrombus from being formed and promoting the early reparation of thebracket endothelium.

The invention relates to an implanted completely bioresorbable blood vessel polymer support which comprises five or more annular wave-shaped supporting rods and connecting rods connected between the supporting rods at intervals. The supporting rods of the support are formed by alternately connecting quasi-arc-shaped waves and quasi-m-shaped waves, wherein the quasi-arc-shaped waves and the quasi-m-shaped waves are formed by connecting two sets of forward s and inverted s respectively, and every two adjacent supporting rods are connected by connecting the tops of the quasi-arc-shaped waves and the bottoms of the quasi-m-shaped waves through the corresponding connecting rod. The net pattern form of the polymer support is carved on a thin wall pipe through lasers. According to the scheme, the contradiction among the radial supporting force, the wall thickness and flexibility of the polymer support is resolved, the radial supporting force, the wall thickness and flexibility are considered at the same time, good passage capacity is achieved, enough mechanical supporting can be given to a lesion segment within the specific time of injury healing, the support is gradually absorbed by the body after injury healing, endothelialization is good, and the stenosis rate of the support and the risk of the support in later stent thrombosis are reduced effectively.

The invention discloses a combined medical instrument formed by a drug coated balloon and a stent. The combined medical instrument comprises the balloon and the stent, a drug-containing coating is coated outside the balloon, the stent is pressed on the outer wall of the balloon in a held manner, a conduit communicated with the balloon is arranged at one end of the balloon, and the far end of the conduit is connected with a conduit base. By the structure, the novel medical instrument is formed by the drug coated balloon (DCB) carrying drugs and the bare metal stent (BMS), so that the therapeutic effect of low restenosis, similar to that of a drug eluting stent (DES), is achieved through a series of novel design of the balloon and the BMS; meanwhile, late stent thrombosis possibly appearing after the DES is used, the risks brought about by taking anticoagulants for a long period of time, and the financial burden caused by taking the anticoagulants can be avoided; and the novel instrument can be used in a way similar to that of the existing DES, so that the same convenience is achieved.

Methods of treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor, and optionally bivalirudin. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and / or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.

The invention provides a biodegradable rapamycin-prednisone composite medicinal coat metal stent, which comprises a metal stent, and active ingredients and a slow-release carrier wrapping the surface of the metal stent, wherein the active ingredients comprise rapamycin and prednisone, and the slow-release carrier is an in vivo degradable aliphatic polymer. The coat metal stent keeps the advantage of restenosis prevention of a medicinal coat metal stent, and solves the problem of late stent thrombosis along with full release of a slow-release coat; and the prednisone in the coat has the effect of inhibiting local inflammatory response caused by the carrier and the medicament. The coat metal stent of the invention is mainly used for interventional therapy of coronary heart disease, prevention of restenosis and reduction of late thrombosis formation after the stent is implanted.

The invention discloses a vascular drug stent, which comprises a vascular stent and drug borne by the stent. The drug refers to a compound of paclitaxel and derivatives thereof, hirudin and recombinant products thereof. By adopting the compound consisting of paclitaxel and derivatives thereof that can effectively reduce restenosis as well as hirudin and recombinant products thereof that can most effectively and directly restrain the thrombin, the vascular drug stent eliminates coating materials and applies the drug loading technique by micropores, to realize stable release of the drug by overcoming the surface tension, thus avoiding the inflammation and thrombosis caused by the coating materials, and at the same time getting rid of untoward effect between the coating materials and the drugs. The vascular drug stent with the compound of paclitaxel and derivatives thereof, hirudin and recombinant products thereof can further reduce restenosis rates of drug-eluting stents as well as risks of stent thrombosis.

The invention provides a drug delivery carrier containing TGF (transforming growth factor) alpha-Saporin and a preparation method of the carrier. The drug delivery carrier comprises a carrier body and a drug coating, wherein the drug coating wraps the carrier body; the drug coating comprises at least one TGF alpha-Saporin drug layer wrapping the surface of the carrier body and at least one macromolecule polymer layer wrapping the outmost layer of the TGF alpha-Saporin drug layer. According to the drug delivery carrier, a common drug delivery carrier is coated with TGF alpha-Saporin which can selectively inhibit smooth muscle cell proliferation and promote endothelialization of injured vessels at the same time, and thus the coating stent can effectively inhibit vascular restenosis and lower the occurrence rates of post-stent implantation stent thrombosis and acute major adverse cardiovascular events.

The invention discloses medical application of berberine. The berberine has prominent functions of resisting noradrenaline and stimulating pulmonary arterial smooth muscle cells and is capable of effectively improving the function of a right ventricular, and meanwhile, the berberine is capable of remarkably reducing mean pulmonary arterial pressure; the functions of preventing in-stent restenosis and stent thrombosis are obtained; the berberine has a unique function of preventing and treating myocardial infarction; the berberine is capable of effectively preventing and treating ischemic cardiomyopathy and cardiac failure caused thereby.

The invention discloses a coating intravascular stent with chitosan carrying siRNA and a preparation method of the coating intravascular stent and belongs to the technical field of intravascular stents. The intravascular stent comprises a stent body. A nanometer coating is arranged on the outer surface of the stent body. The nanometer coating is a nanometer coating with the hydroxylbutyl chitosan carrying the tissue factor siRNA. The invention further provides the preparation method of the intravascular stent. The preparation method includes the steps that the tissue factor siRNA is constructed, hydroxylbutyl chitosan nanometer particles carrying the tissue factor siRNA are prepared, alkali treatment is performed on the surface of a bare metal intravascular stent, and the nanometer coating with the hydroxylbutyl chitosan carrying the tissue factor siRNA is prepared. According to the preparation method, the hydroxylbutyl chitosan is made into nanometer particle compounds through the nanometer technology, the hydroxylbutyl chitosan nanometer compounds carrying the tissue factor siRNA are attached to the intravascular stent, RNA genes are quiet by releasing tissue factors, excessive hyperplasia of smooth muscle cells is inhibited, and stent thrombosis and restenosis are prevented.

The invention relates to an application of a novel slide buckle bio-absorbable stent in manufacture of a cardiovascular system or a lumen stent for cardiovascular or luminal stenosis diseases. The application has the advantages as follows: the novel slide buckle bio-absorbable stent has good degradability and biocompatibility and is applicable to pediatric intravascular stents, and late stent thrombosis cannot occur after implantation, so that antiplatelet drugs are not required to be taken for a long time, and possible subsequent surgical operations cannot be affected; the support force is high, the novel slide buckle bio-absorbable stent can be taken as a cardiovascular system stent or a lumen stent and can be widely applied in the cardiovascular or luminal stenosis diseases; the manufacture is simple and convenient, medicine carrying is facilitated, and the stent can be used as a drug or gene therapy carrier; the stent is equipped with a delivery system at the same time, and the operation difficulty is reduced; and a large number of animal experiments show that the novel slide buckle bio-absorbable stent has a higher success rate during the usage, the curative effect is remarkable, and the stent has a better clinical application prospect.

A multilayer bioresorbable stent having sustained drug delivery is disclosed herein. The bioresorbable stent releases a therapeutic substance from the body of the bioresorbable stent starting when the bioresorbable stent is implanted within an anatomical lumen and ending when the entire mass of the bioresorbable stent is no longer present within the anatomical lumen. The bioresorbable stent releases the therapeutic substance gradually during the treatment as the mass of the each layer of the bioresorbable stent erodes. Methods of making the therapeutic layers within the bioresorbable sent are further disclosed. Sustained drug delivery reduces the risk of late and very late stent thrombosis.

Provided is a stent wherein cells are directionally proliferated on the inner surface of the stent and thus the stent surface is quickly coated with the cells so that the onset of late stent thrombosis or restenosis can be prevented or reduced. The stent (10) comprises a cylindrical main stent body (12), which has openings at both ends and extends along the longitudinal direction (X) between said openings at the both ends, and a coating layer (13), which is provided on the inner surface of the main stent body (12) and contains a substance having a cell adhesion ability to promote the adhesion of cells, said coating layer (13) being formed by arranging multiple linear coating parts (14), each extending linearly, in a striped manner.

The invention relates to an intravascular stent technology, and discloses an artery drug eluting stent based on the 3D printing technology and a preparation method thereof. The stent comprises a plurality of stent beams, and a stent body is made of metal materials; seen from the section of the stent, the stent comprises a solid structure body and a drug carrying body of a porous structure, the drug carrying body is located on the side, facing the vascular wall, of the stent, the drug carrying body comprises a surface layer on the outer surface and the internal porous structure, the surface layer is provided with a plurality of release holes, and the stent body is integrally formed through the 3D printing technology. By applying the stent, restenosis and stent thrombosis caused by the defect of the stent technology can be effectively avoided, the 3D printing technology can achieve the stent metal porous structural design, and the innovative thinking of drug carrying inside the stent canbe completed.

The invention discloses use of a novel bioresorbable slide fastener scaffold as a cardiovascular system scaffold or endoluminal stent for cardiovascular disease or luminal stenosis disease. The invention has the advantages that: the novel bioresorbable slide fastener scaffold has good degradability and biocompatibility, is more suitable for a blood vessel scaffold in paediatrics, and cannot causelate stent thrombosis after being implanted so as to ensure that the patient does not need taking an anti-platelet agent for a long time and the subsequently possible surgical operation cannot be influenced; the novel bioresorbable slide fastener scaffold has strong support force, and can serve as the cardiovascular system scaffold or endoluminal stent to be widely applied to the cardiovascular disease or luminal stenosis disease; the novel bioresorbable slide fastener scaffold is easy and convenient to manufacture, is convenient to load medicines and can be used as a carrier of medicines or a vector for gene therapy; the scaffold is equipped with a deliver system to reduce the surgical operating difficulty; and a large number of animal experiments prove that the novel bioresorbable slidefastener scaffold has higher success rate during use, obvious treatment effect and better clinical application prospect.

The invention relates to an intravascular stent, and discloses a drug eluting stent and a preparing method thereof. The drug eluting stent comprises multiple stent beams, and the stent body is made from a metal material or a biological absorbable material; in the aspect of the cross sections of the stent beams, the drug eluting stent comprises a solid structure body and a drug carrier of a porousstructure, the drug carrier is located at the side, facing the blood vessel wall, of the stent, the drug carrier comprises a surface layer of the outer surface and the porous structure inside, the surface layer is provided with multiple releasing holes, and restenosis and stent thrombosis triggered by the defects of the stent technology can be effectively avoided. The stent porous structure designcan be achieved through a 3D printing technology, and innovative thinking for carrying drugs inside the stent can be completed.

The invention discloses a novel drug-coated stent. The novel drug-coated stent comprises a stent body and a drug coating applied to the stent body, wherein the drug coating comprises drug and a drug carrier, the drug contains a tissue factor pathway inhibitor which is TFPI-1or TFPI-2, and the mass ratio of the drug to the drug carrier is 1:(8-12). The drug further contains one or two of sirolimus drug, taxol drug and statin drug. The thickness of the drug coating is 100-230 microns. The novel drug-coated stent has the advantages that stent thrombosis incidence can be reduced, the rate of recurrence of infarction and fatality rate of patients can be reduced remarkably, and long-term prognosis can be improved; usage of antiplatelet drugs and anticoagulant drugs is reduced, and the occurrence rate of bleeding events is reduced; the tissue factor pathway inhibitor is tissue factor physiological inhibitor, has high blood compatibility and histocompatibility, and is free of toxic or side effect and has few influences on human body.

A novel drug-coated balloon comprises a balloon and a drug coating coated on the balloon. The drug coating comprises a drug and a drug carrier, the drug is a tissue factor pathway inhibitor which is TFPI-1 or TFPI-2, and the mass ratio of the drug to the drug carrier is 1:(2-3.9). The outer wall of the balloon is provided with the drug coating, and the thickness of the drug coating ranges from 8 micrometers to 15 micrometers. The novel drug-coated balloon has the advantages that the incidence rate of no-reflow phenomenon of PCI postoperation of a patient can be decreased; the incidence rate of stent thrombosis of the patient can be decreased; the reinfarction rate and the fatality rate of the patient are obviously decreased, and long-term prognosis of the patient is improved; the tissue factor pathway inhibitor is a physiological inhibitor of a tissue factor; compared with other drugs, the novel drug-coated balloon has good blood compatibility and tissue compatibility and is free of toxic and side effects and small in influence on a human body.

The present invention is directed to the use of cangrelor for the treatment and / or prevention of shunt thrombosis in patients suffering congenital heart diseases undergoing shunt surgery. The invention is also directed to the use of cangrelor for the treatment and / or prevention of stent thrombosis in pediatric patients undergoing stent implantation.